A Cross Sectional Study to Assess Liver Fibrosis in Patients with Diabetes and Metabolic Syndrome

  • Syed Safiullah Ghori Department of Endocrinology,Osmania General Hospital,Afzalgung,Hyderabad Telangana, India.
  • Hafsa Khalid Department of Endocrinology,Osmania General Hospital,Afzalgung,Hyderabad Telangana, India.
  • Mohammed Alim Department of Endocrinology,Osmania General Hospital,Afzalgung,Hyderabad Telangana, India.
  • Mohammed Abdul Quddus Department of Endocrinology,Osmania General Hospital,Afzalgung,Hyderabad Telangana, India.
Keywords: fibrosis, enhanced liver fibrosis, non-alcoholic fatty liver disease, cirrhosis, NAFLD fibrosis score, BARD score.

Abstract

The present study was conducted in Osmania General Hospital,Hyderabad.The study included evaluation of liver fibrosis in patients with diabetes and metabolic syndrome. Liver fibrosis is now being considered as reversible process which is characterized by excessive accumulation of extra cellular matrix. The use of non-invasive methods to assess liver fibrosis in patients with HCV, Non-Alcoholic Fatty Liver Disease (NAFLD) and alcohol abuse has been well validated. However use of these non-invasive methods in patients with diabetes mellitus and metabolic syndrome assessed might develop fibrosis during asymptomatic stages. Hence we tried to use these non-invasive methods in patients with diabetics and metabolic syndrome who are at high risk of developing NAFLD or liver fibrosis in routine clinical practice. This was a single center, prospective study. 50 patients with diabetes and metabolic syndrome attending the endocrinology department of Osmania General Hospital were assessed for fatty liver and enrolled in to the study. NAFLD fibrosis score was used to assess liver fibrosis and BARD score was used for staging of fibrosis as per metavir classificationThe mean age of the patients was 50.8 ± 8.2 with 22 males and 28 females. 90% of the population was found to have some degree of fibrosis. 56% of the patients were at advance fibrosis stage as per the BARD score.Patients with diabetes and metabolic syndrome should be constantly evaluated for liver fibrosis apart from development of diabetes and other complications and to prevent any adverse effects due to waning of liver functions.
Published
2017-05-25